ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology’s proprietary linker-payload ...

New facility is expected to serve as a global hub for accelerating the development of next-generation antibody-drug conjugates for the treatment of cancer. Boehringer Ingelheim announced the official ...

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Neoantigen vaccine is a promising breakthrough ...

1Department of Pathology, Yale University School of Medicine, New Haven, Connecticut. 2Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Sotiria ...

The new facility will serve as a leading research center for advancing antibody-drug conjugates ( ADC ) research and development, supporting Boehringer Ingelheim’s commitment to developing ...

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai 201203, China State Key Laboratory of Drug Research, Shanghai ...

IPH4502 is a novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) conjugated to exatecan targeting Nectin-4, a cell adhesion molecule that is overexpressed in several types ...

Attribution (BY): Credit must be given to the creator. Immunoreagents, most commonly antibodies, are integral components of lateral flow immunoassays. However, the use of antibodies comes with ...

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile New antibody-drug conjugate (ADC) candidate ...